Kowbird in Oakland closes, according to owner
'Despite the love and support we've received from the community, the climate for small businesses, particularly restaurants, has become increasingly difficult,' Horn said. 'This is not a reflection of the people who have been our loyal customers and supporters over the years. In fact, it's the complete opposite — their unwavering belief in us has been a beacon of hope. But the broader climate — the challenges that small businesses and restaurants face in Oakland — has proven to be a constant uphill battle.'
Man accused by Khazar Momeni tries to clear his name after Bob Lee trial
Horn, who also operated Horn Barbecue in West Oakland, said there was a 'lack of meaningful support for small businesses' in Oakland, and a 'lack of framework' to 'nurture and sustain' them.
'It's disheartening to see how small businesses like ours are overlooked,' said Horn, 'and it's even harder to face the financial and emotional toll it takes on the people who make it all happen.'
Kowbird opened in 2022 and closed in early January, according to the San Francisco Chronicle. In November, Kowbird was sued for alleged American with Disabilities Act (ADA) violations. Horn's other restaurant, Horn Barbecue, was temporarily closed in 2023 after a fire that was investigated as arson.
Over the years, Horn's restaurants have been subject to lawsuits and wage claims from former employees. In his statement on Kowbird, Horn said 'the media's obsession with highlighting these challenges, often sensationalizing the struggles of small businesses, is, frankly, confusing.'
'However, it seems the press's appetite for emphasizing the downfall of small enterprises is something that must be accommodated,' he added.
Kowbird was known for its hot chicken sandwiches and 'soulful dishes that pay homage to culture and comfort,' according to its website.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
a day ago
- The Hill
Costly employer lesson: Remote work isn't just a perk when it comes to disability rights
Amazon's mirrored towers dominate Seattle's skyline, yet the company's real power struggle plays out far from the city streets. Disabled employees who rely on telework for everything from chronic-pain management to post-stroke recovery suddenly face a blunt mandate: 'Show up five days a week or find another job.' Several workers filed complaints with the Equal Employment Opportunity Commission, and the National Labor Relations Board and supplied regulators with a list of 18 colleagues in similar straits. The complaints accuse Amazon of using AI bots to screen doctors' notes, deleting internal posts that question the policy, and retaliating against staff who demand legally protected accommodations. The Americans with Disabilities Act views telework as a textbook 'reasonable accommodation' whenever physical presence is not an essential job function. The EEOC's 2003 telework guidance spells that out in plain language. Two decades later, the agency has doubled down, warning employers that algorithms must never replace the human dialogue that the ADA demands. When an employee's disability collides with commuting or open-plan offices, the employer must engage in an interactive process and prove undue hardship before denying remote work. Blanket return-to-office rules skip that step, inviting litigation. Amazon's 'multilevel leader review' and month-long trials add procedural hurdles that look less like dialogue and more like deterrence, a strategy that courts routinely punish. Data corroborate the law. The Bureau of Labor Statistics reports that 22.7 percent of Americans with disabilities held jobs in 2024 — the highest share since tracking began in 2008. Economists at the Centre for Economic Policy Research estimate that roughly three-quarters of the surge — nearly 250,000 full-time roles — came directly from the spread of work-from-home options. Remote work eliminates transportation barriers, spares workers from sensory-overloaded offices, and allows flexible scheduling for medical appointments. Employers reap measurable dividends: higher retention, larger talent pools, and productivity bumps that mirror Stanford research showing that teleworkers lose 60 million fewer commuting hours each day. By curbing telework, companies abandon those gains and shrink their competitive edge. The cost of Amazon's decision already extends beyond internal morale. News of deleted Slack posts, AI-driven denials and a petition circulates through human resources newsletters, tech forums and mainstream finance pages. Analysts cast the five-day mandate as an 'outdated' model that helps explain why Amazon's stock lags Alphabet and Microsoft. Marketers understand the math: lower sentiment drives up customer-acquisition costs, dents Amazon Prime sign-ups, and chills advertisers that do not want their brands adjacent to negative headlines. Legal exposure compounds the reputational hit. Jury verdicts show how quickly ADA cases escalate. For example, a jury gave a $22.1 million award against Wells Fargo last year for dismissing an employee who requested remote work due to a disability. Amazon's headcount dwarfs that of Wells Fargo's workforce, and the 18 'similarly situated' employees already named in EEOC filings represent a fraction of the staff who could assert similar claims. Even if settlements land well below eight figures, each lawsuit refreshes the news cycle and generates new discovery costs, outside-counsel fees and managerial distraction that dwarf whatever efficiency leaders hope to gain from rigid attendance rules. Amazon's internal survey results hint at wider risk. Seventy-one percent of the more than 200 disabled employees who responded said the company denied most accommodation requests, and half reported a hostile environment after disclosure. One stroke survivor was advised to move closer to the office; another worker with chronic pain who couldn't drive for longer than 15 minutes was told to ' pull over and stretch ' during a freeway commute. Those anecdotes may never headline a trial, yet they shape jury pools and public opinion long before a judge gavels in the first hearing. Companies and government agencies copying Amazon's return-to-office mandate should consider the mounting toll elsewhere. Bell Road Tire in Arizona paid $64,500 and entered a consent decree after the EEOC found the company had forced a disabled mechanic back to the shop without an interactive dialogue. Federal agencies scrambling to meet sweeping workplace orders already face chaotic space shortages and escalating accommodation disputes, conditions ripe for similar exposure. The U.S. Treasury Department warned recently that it faces significant legal exposure due to a massive accumulation of unanswered requests for remote work. A surge in disability accommodation pleas, primarily for telework, followed a return-to-office mandate from the Trump administration. With thousands of these requests pending for months — far exceeding the mandated 20-day response time — department officials anticipate a wave of expensive equal employment opportunity lawsuits. As those and other stories surface, the resulting lawsuits and negative coverage will replicate Amazon's experience, multiplying costs across the public and private sectors. Remote work transforms the ADA's promise of equal opportunity from statute into daily reality. Enabling telework costs little, widens talent pipelines and signals respect. Denying it by blanket edict gambles with lawsuits, investor skepticism and brand erosion. Amazon's clash with disabled employees proves that the price of inflexibility climbs faster than any savings squeezed from a full parking lot. Leaders who still view remote work as a perk rather than a legal and strategic imperative risk learning the same expensive lesson, under the harsh glare of both courtroom lights and public scrutiny. Gleb Tsipursky, Ph.D., serves as the CEO of the hybrid work consultancy Disaster Avoidance Experts and authored the best-seller ' Returning to the Office and Leading Hybrid and Remote Teams.'
Business Journals
5 days ago
- Business Journals
From concept to capacity — Faster parking for South Florida's healthcare systems
For healthcare administrators and real estate developers, parking isn't just a line item, it's a critical part of patient experience and operational flow. But building new structured parking on an active medical campus? That's where things get complicated. You're balancing permit approvals, tight site logistics, and stakeholder pressure—all while trying to avoid service disruption and keep costs predictable. That's why some of Florida's leading hospital systems are turning to partners who've done this before—many times over. With more than two dozen healthcare parking structures completed across the state, FINFROCK understands the stakes. We've delivered for major systems in Miami, Orlando, Jacksonville, and beyond, solving complex challenges while keeping timelines and budgets on track. Built for the Pace (and Pressure) of Healthcare FINFROCK has designed, manufactured, and constructed more healthcare parking structures in Florida than any other firm. With over 300 precast parking structures nationwide and more than two dozen hospital-related projects completed statewide—including major facilities in Miami, Boca Raton, Orlando, and Jacksonville, our team understands the operational demands that come with building on a healthcare campus. We know what it means to stage materials in tight footprints. We know how to phase work around emergency access routes. We know how to communicate with facilities teams to keep disruptions low. And most of all, we know how to finish on time. Even when the schedule is aggressive. expand Unlike typical construction firms, FINFROCK is a vertically integrated design-builder. That means we combine architecture, engineering, precast concrete manufacturing, and general contracting under one roof. The result? A seamless process where pricing, design, and construction planning happen concurrently, eliminating guesswork and giving you cost certainty from the start. expand When you work with FINFROCK, there's no need to manage handoffs between multiple firms. You're working with one experienced partner who owns the entire process—from concept to capacity. And because our structures are manufactured in-house, we can maintain a pace that other builders simply can't match while maintaining strict quality standards and structural durability built for decades of 24/7 hospital traffic. Unlike traditional cast-in-place methods where the focus often ends at the first pour, FINFROCK's precast concrete is a true lifecycle solution, designed and built with longevity, efficiency, and long-term value in mind. As both architect and builder, we consider how a structure will perform for decades, not just how it stands on day one. Check out the Case Study: Boca Raton Regional Hospital What This Means for Your Project Modular, integrated delivery isn't a gimmick—it's a strategic tool. Here's how it works for healthcare: You get an early, reliable price—before drawings are set Design issues—ranging from utilities to ADA access—get resolved fast Construction cranes can work efficiently between active buildings Parking becomes an asset, not a liability, improving patient and staff experience Capacity on Your Terms Building for healthcare means hitting delivery dates without jeopardizing patient access, budgets, or safety. With FINFROCK's advanced modular and single-source model, capacity comes on your terms: fast, efficient, and predictable. If delivering parking for your South Florida healthcare project is on the table, talk to FINFROCK early. We simplify the infrastructure behind the care so your teams can focus on what matters most. Don't let parking delay your healthcare development. FINFROCK helps hospitals and medical centers get spaces online faster with integrated design-build solutions. Contact us to get started. FINFROCK, Florida's top design-builder, integrates architects, engineers, manufacturing, and construction professionals to lower costs, speed-up schedules, and minimize building risk for owners. With over 75+ years' experience, FINFROCK has delivered award-winning buildings including parking, hotels, and luxury multi-family developments, earning top industry rankings and multiple design excellence awards. Dan Helmick, PE, executive VP of project development, propels multi-million-dollar projects, securing key developments with his design and sales background. His strategic vision ensures success, a vital asset to FINFROCK's leadership team.
Yahoo
5 days ago
- Yahoo
Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes
Data Demonstrate that Sana's Hypoimmune (HIP)-Modified Pancreatic Islet Cells, Transplanted with No Immunosuppression, Persist and Function Over Time in Patient with Type 1 Diabetes Study Establishes Ability to Genetically Modify and Transplant Pancreatic Islet Cells Without Immunosuppression and Overcome Both Allogeneic and Autoimmune Rejection Six-Month Patient Follow-up Results Presented at the 85th Annual American Diabetes Association (ADA) Scientific Sessions Further Demonstrate that Sana's HIP-Modified Pancreatic Islet Cells are Safe and Well-tolerated, Survive, Evade Detection by the Immune System, and Continue to Produce Insulin in the Patient Sana Is Incorporating its HIP Technology to Develop SC451, a HIP-Modified, Stem Cell-Derived Therapy as a One-Time Treatment for Patients with Type 1 Diabetes, with a Goal of Normal Blood Glucose with No Insulin and No Immunosuppression Recent FDA INTERACT Meeting Increases Confidence in Moving Forward with GMP Master Cell Bank for SC451 and in Filing SC451 Investigational New Drug Application (IND) as Early as 2026 Sana Expects Study Data to Be Generalizable across Multiple Cell Types and Patient Populations SEATTLE, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that the New England Journal of Medicine (NEJM) has published a journal article titled 'Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression' (DOI: 10.1056/NEJMoa2503822). The article discusses 12-week results from an investigator-sponsored trial, conducted at Uppsala University Hospital, evaluating the transplantation of UP421, a primary human pancreatic islet cell therapy engineered with Sana's hypoimmune (HIP) technology, without the use of immunosuppressive medications in a 42-year-old patient living with type 1 diabetes for over three decades. The intramuscular transplantation of HIP-modified pancreatic islet cells is safe and well-tolerated and demonstrates that these cells evade autoimmune and allogeneic immune recognition, persist, and secrete insulin in a glucose-dependent manner over the 12-week evaluation period reported in the article. 12-week PET-MRI scanning also confirmed islet cells at the transplant site. Six-month data, described below, were recently presented at the ADA meeting and presented today at the World Transplant Congress 2025 concurrently with the publication of the NEJM article. 'We are thrilled to have the results of this study, which we believe represent both a scientific and medical breakthrough, recognized in the New England Journal of Medicine,' said Per-Ola Carlsson, MD, Study Principal Investigator, Senior Physician and Professor at the Clinic for Endocrinology and Diabetology at Uppsala University Hospital. 'Type 1 diabetes is a disease in which the immune system destroys the beta cells in pancreatic islets, requiring the patient to receive lifelong insulin therapy to control glucose levels. Although it is well established that pancreatic islet cell transplantation at a target therapeutic dose can predictably allow patients with type 1 diabetes to live without insulin therapy, until now these patients must take lifelong, significant immunosuppression, which is frequently toxic and difficult to tolerate. This study shows that Sana's novel HIP-modified pancreatic islets restore insulin production without the need for immunosuppression, a transformative outcome and significant step toward a broadly accessible, functional cure for patients with type 1 diabetes. The patient is making his own insulin for the first time in over 35 years.' 'These peer-reviewed results, built upon the extensive preclinical and translational studies of Dr. Sonja Schrepfer and the team at Sana, reinforce our belief that Sana has the capability to develop a functional cure for the broad population of individuals living with type 1 diabetes,' said Steve Harr, MD, Sana's President and Chief Executive Officer. 'The data, together with recent FDA feedback regarding our HIP-edited master cell bank for GMP manufacturing and our non-clinical testing plan for SC451, increase our confidence in our goal for treating type 1 diabetes—a single treatment with no immunosuppression that leads to long-term normal blood glucose without exogeneous insulin. We expect to file an IND for SC451, a next generation HIP-modified, stem cell-derived pancreatic islet therapy, as early as 2026 and begin Phase 1 testing shortly thereafter. I want to thank the entire Sana team, the investigators at Uppsala, and the patient who volunteered for this transformative, first-in-human study.' James Shapiro, M.D., Professor of Surgery, Medicine, and Surgical Oncology at the University of Alberta and leader of the clinical team that developed the Edmonton Protocol for islet cell transplantation, added 'Exogenous insulin therapy remains a lifesaving therapy in the short term, but it falls short of replicating the precise and dynamic glucose regulation of a healthy pancreas, leaving patients susceptible to both short- and long-term medical complications. This limitation motivated my team and me to pioneer a protocol for islet cell transplantation with immunosuppression and to continue innovating in this field. The data presented in the NEJM article—demonstrating that transplanted, engineered islet cells can both evade immune-mediated destruction and respond appropriately to insulin demands—represent a significant advancement in the ongoing pursuit of a definitive cure for type 1 diabetes and support my long-held belief that the future of type 1 diabetes treatment is in stem cell-based therapies.' Key Findings from Ongoing Study No serious adverse events or adverse events possibly or probably related to UP421 were identified in the study. HIP-modified pancreatic islet cells, transplanted with no immunosuppressive medicines, including no glucocorticoids, evade immune detection and rejection. Pancreatic islet cells survive and function post-transplantation. The survival and function of the HIP-modified pancreatic beta cells was confirmed at each blood draw, as measured by the presence of circulating C-peptide, a biomarker indicating that transplanted beta cells are producing insulin. C-peptide levels increase during monthly mixed meal tolerance tests (MMTT), showing increased insulin secretion in response to a meal. Of note, prior to transplant, the patient had undetectable C-peptide both when fasting and during an MMTT. MRI scans at each month show a sustained and consistent signal at the site of cell transplantation, consistent with graft survival. A PET-MRI scan with a tracer targeting pancreatic beta cells confirms that the surviving cells are, in fact, pancreatic beta cells. Sign in to access your portfolio
